HomeCompareAMTY vs JNJ

AMTY vs JNJ: Dividend Comparison 2026

AMTY yields 5000.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AMTY wins by $62217131802825.32M in total portfolio value
10 years
AMTY
AMTY
● Live price
5000.00%
Share price
$0.04
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$62217131802825.35M
Annual income
$59,861,980,287,378,210,000.00
Full AMTY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — AMTY vs JNJ

📍 AMTY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAMTYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AMTY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AMTY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AMTY
Annual income on $10K today (after 15% tax)
$425,000.00/yr
After 10yr DRIP, annual income (after tax)
$50,882,683,244,271,480,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, AMTY beats the other by $50,882,683,244,271,480,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AMTY + JNJ for your $10,000?

AMTY: 50%JNJ: 50%
100% JNJ50/50100% AMTY
Portfolio after 10yr
$31108565901412.69M
Annual income
$29,930,990,143,689,110,000.00/yr
Blended yield
96.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

AMTY
No analyst data
Altman Z
-14.4
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AMTY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAMTYJNJ
Forward yield5000.00%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$62217131802825.35M$30.3K
Annual income after 10y$59,861,980,287,378,210,000.00$4,689.40
Total dividends collected$62057786341622.61M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AMTY vs JNJ ($10,000, DRIP)

YearAMTY PortfolioAMTY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$510,700$500,000.00$10,592$272.30+$500.1KAMTY
2$24,410,935$23,864,485.98$11,289$357.73+$24.40MAMTY
3$1,092,192,501$1,066,072,800.30$12,123$472.89+$1092.18MAMTY
4$45,746,366,951$44,577,720,975.17$13,141$629.86+$45746.35MAMTY
5$1,793,932,828,410$1,744,984,215,772.56$14,408$846.81+$1793932.81MAMTY
6$65,871,973,805,320$63,952,465,678,921.49$16,021$1,151.60+$65871973.79MAMTY
7$2,265,146,887,602,700$2,194,663,875,631,007.20$18,122$1,588.22+$2265146887.58MAMTY
8$72,954,689,148,998,180$70,530,981,979,263,280.00$20,930$2,228.20+$72954689148.98MAMTY
9$2,201,076,182,660,884,700$2,123,014,665,271,456,500.00$24,792$3,191.91+$2201076182660.86MAMTY
10$62,217,131,802,825,350,000$59,861,980,287,378,210,000.00$30,274$4,689.40+$62217131802825.32MAMTY

AMTY vs JNJ: Complete Analysis 2026

AMTYStock

Amerityre Corporation engages in the research and development, manufacture, and sale of polyurethane tires in the United States. The company provides closed-cell polyurethane foam tires for bicycles, golf and baggage carts, hand trucks, lawn and garden equipment, wheelbarrows, personnel carriers, and medical mobility products, as well as custom designed applications; polyurethane elastomer industrial tires for forklifts and scissor lifts; agricultural tires, including seeder tires and hay baler tires, as well as flat-free pivot tires that are used in irrigation systems; and specialty tires and tire-wheel assemblies. It serves original equipment manufacturers of lawn and garden products, and outdoor power equipment; regional tire distributors; retail cooperatives; agricultural tire distributors; and retailers of lawn and garden products, bicycle tires, and hand truck tires. The company was formerly known as American Tire Corporation and changed its name to Amerityre Corporation in December 1999. Amerityre Corporation was founded in 1995 and is headquartered in Boulder City, Nevada.

Full AMTY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this AMTY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AMTY vs SCHDAMTY vs JEPIAMTY vs OAMTY vs KOAMTY vs MAINAMTY vs ABBVAMTY vs MRKAMTY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.